¸²ÇÁÁ¾¿¬±¸È¸ CISL33 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ¸ðÀÓ : 2023-02-25±³À°ÀÏÀÚ : 2023-02-25
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü
±³À°ÁÖÁ¦ :
CISL33 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ¸ðÀÓ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 13:10~13:25 A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma ÀÓÈ£¿µ(ÀüºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 13:25~13:40 A Phase II Study of Epigenetic Priming Using Azacitidine Followed by R-GDP Immunochemotherapy in Patients with Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma È«ÁؽÄ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 13:40~13:55 Multicenter Prospective Cohort Study of Hodgkin Lymphoma ¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 13:55~14:10 Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma who are at high risk of central nervous system relapse Á¶Çü¿ì(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 14:10~14:25 Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype ±è¼®Áø(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 14:30~14:50 Selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin lymphoma ¼Û°¡¿µ(ȼøÀü³²´ëÇб³º´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 15:10~15:30 phase I/II study of the combination of venetoclax, rituximab and lenalidomide for relapsed or refractory primary central nervous system lymphoma Á¶Çü¿ì(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 14:50~15:10 Retrospective analysis of Infectious events in Lymphoma patients who were treated with bendamustine plus anti-CD20 monoclonal antibody ÀÌÁØÈ£(Áß¾Ó´ëÇб³º´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 15:30~15:50 Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma À±»óÀº(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 15:50~16:10 Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-na?ve, newly diagnosed lowꠓrisk extranodal NK/T-cell lymphoma, nasal type À±»óÀº(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 16:10~16:30 Duodenal-type Follicular Lymphoma in Korean population: A Multicenter Study Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-25 ±¤°èÅä°ü 16:30~17:00 The Antengene Pipeline Includes Multiple Novel Immuno-oncology and Targeted Ass À̵¿¿(¾ÈÅÙÁøÁ¦¾à)